Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
VICORE PHARMA AB currently manages 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 6 distinct examiners. The prosecution spans 5 distinct art units, reflecting the technical distribution of the company's Biotechnology & Pharmaceuticals filings. This distribution across 5 distinct art units indicates that the company's active matters are subject to the specific standards of those assigned art units at the patent office.
The busiest examiner for this portfolio is TCHERKASSKAYA, OLGA V, who is responsible for 1 pending office action. This count of 1 pending office action for the busiest examiner is part of the total 6 pending office actions. With 6 distinct examiners involved, practitioners managing this portfolio must coordinate across individual examiner preferences. The fact that TCHERKASSKAYA, OLGA V handles this workload highlights the distribution of the current prosecution pipeline. This requires a strategy that accounts for the requirements of the 6 distinct examiners across the 5 distinct art units.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| §112 only | 1 (20%) |
| Double-patenting + other | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TCHERKASSKAYA, OLGA V | 1 | 55.5% | +46.4% |
| MCDOWELL, BRIAN E | 1 | 74.0% | +31.0% |
| CHAO, ALLEN | 1 | 60.0% | +0.0% |
| SANCHEZ, JUSTIN CHRISTOPHER | 1 | 87.3% | +12.1% |
| FETTEROLF, BRANDON J | 1 | 51.6% | +18.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18283489 | SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS | SANCHEZ, JUSTIN CHRISTOPHER | 16d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18283489 | SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS | SANCHEZ, JUSTIN CHRISTOPHER | 16d |
| 18577856 | NEW SELECTIVE ANGIOTENSIN II COMPOUNDS | MCDOWELL, BRIAN E | 30d |
| 18999468 | TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | TCHERKASSKAYA, OLGA V | — |
| 17912645 | IMIDAZOLYL THIOPEHENE SULFONYL CARBAMATES FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOTENSIN II | FETTEROLF, BRANDON J | — |
| Art Unit | Apps |
|---|---|
| 1622 | 2 |
| 1615 | 1 |
| 1624 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18999468 | TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | TCHERKASSKAYA, OLGA V | 1615 | §103§112DP | Non-Final OA | — | Pending | Dec 23, 2024 |
| 18577856 | NEW SELECTIVE ANGIOTENSIN II COMPOUNDS | MCDOWELL, BRIAN E | 1624 | §103 | Final Rejection | 30d | Pending | Jan 09, 2024 |
| 18283487 | SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS | CHAO, ALLEN | 1622 | §112 | Final Rejection | — | Pending | Sep 22, 2023 |
| 18283489 | SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS | SANCHEZ, JUSTIN CHRISTOPHER | 1622 | §103DP | Final Rejection | 16d | Pending | Sep 22, 2023 |
| 17912645 | IMIDAZOLYL THIOPEHENE SULFONYL CARBAMATES FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOTENSIN II | FETTEROLF, BRANDON J | 1626 | §103DP | Final Rejection | — | Pending | Sep 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVICORE PHARMA AB has 5 pending office actions as of October 2026, spread across 4 art units and 5 examiners.
Olga V Tcherkasskaya has the most, with 1 of VICORE PHARMA AB's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
